# HERKULES-3 (NCT05039177)

> A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

No report yet. It can be ordered.

- Drugs tested: ERAS-007 plus encorafenib plus cetuximab; ERAS-007 plus palbociclib
- Indication: metastatic colorectal cancer or pancreatic ductal adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05039177
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Erasca, Inc.
- Conditions: Metastatic Colorectal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions: ERAS-007; Encorafenib; Cetuximab; Palbociclib
- Enrollment: 101
- Primary outcome: Dose Limiting Toxicities (DLT)
- Primary outcome: Maximum Tolerated Dose (MTD)
- Primary outcome: Recommended Dose (RD)
- Primary outcome: Adverse Events

## Indexed commentary on HERKULES-3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=herkules-3-nct05039177

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05039177", "email": "<work email>"}; the inbox owner confirms by the emailed link.